5 Key Takeaways

• 1

  TECLens secured $10 million in Series A2 extension financing for its quantitative corneal cross-linking (qCXL) platform.

• 2

  The funding will support the expansion of TECLens' first-in-human proof-of-concept program and additional clinical data generation.

• 3

  TECLens' CXLens System reshapes the cornea using personalized ultraviolet light patterns without cutting or removing tissue.

• 4

  The ongoing proof-of-concept study focuses on evaluating qCXL for refractive errors, particularly presbyopia.

• 5

  TECLens will present updates on its clinical development program at the ESCRS meeting and the American Academy of Ophthalmology meeting.